Incyte Corporation - Pemazyre FDA Approval Transcript
Greetings. And welcome to the Pemazyre FDA approval conference call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to introduce your host, Mike Booth, Head of Investor Relations for Incyte. Please go ahead, Mike.
Thank you, Kevin. Good morning. And welcome to our conference call and webcast to discuss the FDA approval of Pemazyre, which was announced late Friday. I'm joined on the call today by Hervé, Steven and Barry, who will deliver our prepared remarks; and by Christiana, who will participate in the Q&A session.
(Operator Instructions) I also ask that we seek to split the Q&A session, first, asking questions related to Pemazyre and cholangiocarcinoma; and towards the end of the hour, transitioning to any COVID-19 topics that you might wish to raise.
Before we begin, I must remind you that safe harbor rules govern our remarks today and any forward-looking statements that we may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
